10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure ...
Uniqure NV shares (NASDAQ:QURE) closed July 9 at $6.67, up $2.89, or 76%, after the firm made public updated interim data including up to 24 months of follow-up findings from 29 treated patients ...
Following the discussions about President Trump's 2005 tax returns on Rachel Maddow's show last night (more from Forbes' Dan Alexander on that here), I immediately received questions about the AMT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results